Apollomics News and Activities

Apollomics is a company listed under the stock ticker APLM (US).

View the org chart displaying its 15 main executives

Most searched biographies at Apollomics

• Howard Chen, Chief Executive Officer and Chairman of the Board
• Frank Chu, Independent Director
• Moses Chen, Independent Director

Popular executive movements at Apollomics

• Claudia Huang has joined the company as Independent Director  (posted on November 18 2025).

Create your alert
to follow the executive moves at Apollomics.

Apollomics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Apollomics

• Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer | Apollomics, Inc.
• Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion | Apollomics, Inc.
• Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75% | Apollomics, Inc.
• Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation | Apollomics, Inc.
• Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update | Apollomics, Inc.
• Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023 | Apollomics, Inc.
• Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference | Apollomics, Inc.
• Presentations | Apollomics, Inc.
• Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq | Apollomics, Inc.
• Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium | Apollomics, Inc.
• View more press releases Close

Social media about Apollomics

• Apollomics on Wikipedia, Google News & Yahoo Finance
• Apollomics on LinkedIn, X (Twitter) & YouTube